

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

Hep-53.4

RRID:CVCL_5765

Type: Cell Line

Proper Citation

CLS Cat# 400200, RRID:CVCL_5765

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5765

Proper Citation: CLS Cat# 400200, RRID:CVCL_5765

Description: Cell line Hep-53.4 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Hepatocellular carcinoma of the mouse

Defining Citation: [PMID:1382443](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Hep-53.4

Synonyms: HEP-53.4, 53.4

Cross References: CLS:400200, Wikidata:Q54882766

ID: CVCL_5765

Vendor: CLS

Catalog Number: 400200

Record Creation Time: 20220624T070800+0000

Record Last Update: 20260830T000510+0000

Ratings and Alerts

No rating or validation information has been found for Hep-53.4.

No alerts have been found for Hep-53.4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Xu S, et al. (2026) Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma. Oncogene, 45(16), 1484.

Guo WW, et al. (2026) CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. International journal of biological sciences, 22(7), 3389.

Ta N, et al. (2026) Targeting p21-High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e76384.

May S, et al. (2025) A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma. Disease models & mechanisms, 18(5).

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer cell, 42(12), 2064.